NZ603777A - Bicyclic compound derivatives and their use as acc inhibitors. - Google Patents
Bicyclic compound derivatives and their use as acc inhibitors.Info
- Publication number
- NZ603777A NZ603777A NZ603777A NZ60377711A NZ603777A NZ 603777 A NZ603777 A NZ 603777A NZ 603777 A NZ603777 A NZ 603777A NZ 60377711 A NZ60377711 A NZ 60377711A NZ 603777 A NZ603777 A NZ 603777A
- Authority
- NZ
- New Zealand
- Prior art keywords
- acetamide
- oxy
- piperidin
- methylethyl
- benzoxazol
- Prior art date
Links
- 229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 title abstract 2
- -1 Bicyclic compound Chemical class 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 3
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 abstract 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 abstract 1
- SARSAGRPTBENPV-RPUINLTESA-N C1C[C@@H](OCC(C)NC(C)=O)CC[C@@H]1C(OC1=C2)=CC1=CC=C2OCC1CC1 Chemical compound C1C[C@@H](OCC(C)NC(C)=O)CC[C@@H]1C(OC1=C2)=CC1=CC=C2OCC1CC1 SARSAGRPTBENPV-RPUINLTESA-N 0.000 abstract 1
- IUPSSQXXRJWJDH-NDXORKPFSA-N C1C[C@@H](OC[C@H](C)NC(C)=O)CC[C@@H]1N1N=C2C=C(OCCC3CC3)C=CC2=C1 Chemical compound C1C[C@@H](OC[C@H](C)NC(C)=O)CC[C@@H]1N1N=C2C=C(OCCC3CC3)C=CC2=C1 IUPSSQXXRJWJDH-NDXORKPFSA-N 0.000 abstract 1
- 101150047265 COR2 gene Proteins 0.000 abstract 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 101100467189 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) QCR2 gene Proteins 0.000 abstract 1
- BFPLMTPHDFFMTG-UHFFFAOYSA-N [1,3]oxazolo[5,4-b]pyridine Chemical compound C1=CN=C2OC=NC2=C1 BFPLMTPHDFFMTG-UHFFFAOYSA-N 0.000 abstract 1
- XRVDKIQEFCJTBZ-UHFFFAOYSA-N [1,3]oxazolo[5,4-c]pyridine Chemical compound C1=NC=C2OC=NC2=C1 XRVDKIQEFCJTBZ-UHFFFAOYSA-N 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 abstract 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 abstract 1
- 239000012964 benzotriazole Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- JMANUKZDKDKBJP-UHFFFAOYSA-N imidazo[1,5-a]pyridine Chemical compound C1=CC=CC2=CN=CN21 JMANUKZDKDKBJP-UHFFFAOYSA-N 0.000 abstract 1
- AFSPJJIONSZSCB-AWEZNQCLSA-N n-[(2s)-1-[1-[5-(cyclopropylmethoxy)-1,3-benzoxazol-2-yl]piperidin-4-yl]oxypropan-2-yl]acetamide Chemical compound C1CC(OC[C@H](C)NC(C)=O)CCN1C1=NC2=CC(OCC3CC3)=CC=C2O1 AFSPJJIONSZSCB-AWEZNQCLSA-N 0.000 abstract 1
- VOPNSNMPYORVQD-LBPRGKRZSA-N n-[(2s)-1-[1-[6-(2,2,2-trifluoroethoxy)-1,3-benzothiazol-2-yl]piperidin-4-yl]oxypropan-2-yl]acetamide Chemical compound C1CC(OC[C@H](C)NC(C)=O)CCN1C1=NC2=CC=C(OCC(F)(F)F)C=C2S1 VOPNSNMPYORVQD-LBPRGKRZSA-N 0.000 abstract 1
- NQFDYRVHKCXJQP-HNNXBMFYSA-N n-[(2s)-1-[1-[6-(2-cyclopropylethoxy)-1,3-benzoxazol-2-yl]piperidin-4-yl]oxypropan-2-yl]acetamide Chemical compound C1CC(OC[C@H](C)NC(C)=O)CCN1C(OC1=C2)=NC1=CC=C2OCCC1CC1 NQFDYRVHKCXJQP-HNNXBMFYSA-N 0.000 abstract 1
- ZTQJADDEMCINFS-AWEZNQCLSA-N n-[(2s)-1-[1-[6-(cyclopropylmethoxy)-1,3-benzoxazol-2-yl]piperidin-4-yl]oxypropan-2-yl]acetamide Chemical compound C1CC(OC[C@H](C)NC(C)=O)CCN1C(OC1=C2)=NC1=CC=C2OCC1CC1 ZTQJADDEMCINFS-AWEZNQCLSA-N 0.000 abstract 1
- MFVUXRRTNVGQNW-HNNXBMFYSA-N n-[(2s)-4-[1-[6-(cyclopropylmethoxy)-1,3-benzoxazol-2-yl]piperidin-4-yl]butan-2-yl]acetamide Chemical compound C1CC(CC[C@H](C)NC(C)=O)CCN1C(OC1=C2)=NC1=CC=C2OCC1CC1 MFVUXRRTNVGQNW-HNNXBMFYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 abstract 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000001076 sarcopenia Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010102718 | 2010-04-27 | ||
| PCT/JP2011/060616 WO2011136385A1 (en) | 2010-04-27 | 2011-04-26 | Bicyclic compound derivatives and their use as acc inhibitors. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ603777A true NZ603777A (en) | 2013-08-30 |
Family
ID=44120718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ603777A NZ603777A (en) | 2010-04-27 | 2011-04-26 | Bicyclic compound derivatives and their use as acc inhibitors. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8703758B2 (enExample) |
| EP (1) | EP2563765B1 (enExample) |
| JP (1) | JP5693611B2 (enExample) |
| KR (1) | KR20130094211A (enExample) |
| CN (1) | CN103025716B (enExample) |
| AR (1) | AR080969A1 (enExample) |
| AU (1) | AU2011246004A1 (enExample) |
| BR (1) | BR112012027648A2 (enExample) |
| CA (1) | CA2797767A1 (enExample) |
| CO (1) | CO6640253A2 (enExample) |
| CR (1) | CR20120598A (enExample) |
| EA (1) | EA021698B1 (enExample) |
| EC (1) | ECSP12012311A (enExample) |
| ES (1) | ES2546130T3 (enExample) |
| GE (1) | GEP20146178B (enExample) |
| MA (1) | MA34245B1 (enExample) |
| NZ (1) | NZ603777A (enExample) |
| PH (1) | PH12012502347A1 (enExample) |
| SG (1) | SG185759A1 (enExample) |
| TW (1) | TW201206911A (enExample) |
| UA (1) | UA108102C2 (enExample) |
| UY (1) | UY33354A (enExample) |
| WO (1) | WO2011136385A1 (enExample) |
| ZA (1) | ZA201208895B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201390794A1 (ru) | 2010-11-30 | 2013-11-29 | Такеда Фармасьютикал Компани Лимитед | Бициклическое соединение |
| EP2772485A4 (en) * | 2011-10-24 | 2015-06-10 | Takeda Pharmaceutical | BICYCLIC CONNECTION |
| US8530460B2 (en) * | 2011-12-19 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Azetidine derivatives |
| US8530461B2 (en) | 2011-12-29 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Azetidine derivatives |
| US8623860B2 (en) * | 2011-12-30 | 2014-01-07 | Boehringer Ingelheim International Gmbh | Azetidine derivatives, pharmaceutical compositions and uses thereof |
| BR112016004118A2 (pt) | 2013-09-12 | 2017-10-17 | Pfizer | uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar |
| JP6050291B2 (ja) * | 2014-08-07 | 2016-12-21 | 長谷川香料株式会社 | ソラノンの製造方法およびその合成中間体 |
| JP2016079168A (ja) * | 2014-10-17 | 2016-05-16 | 塩野義製薬株式会社 | ９員縮合環誘導体 |
| CN106636402B (zh) * | 2016-12-22 | 2020-09-15 | 中南大学湘雅医院 | 一种判断鼻咽癌放疗敏感性的分子标志物及应用 |
| JP7361584B2 (ja) * | 2018-12-19 | 2023-10-16 | 高砂香料工業株式会社 | アミドの還元によるアミンの製造方法 |
| WO2023090411A1 (ja) | 2021-11-19 | 2023-05-25 | 塩野義製薬株式会社 | 心疾患または骨格筋の疾患の治療用医薬 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
| WO2000068213A1 (en) | 1999-05-05 | 2000-11-16 | Aventis Pharma Limited | Substituted bicyclic compounds |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| US6930185B2 (en) | 2000-04-28 | 2005-08-16 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
| US7229986B2 (en) | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
| AU2001269531A1 (en) | 2000-07-17 | 2002-01-30 | Takeda Chemical Industries Ltd. | Sulfone derivatives, process for their production and use thereof |
| EP1478437B1 (en) * | 2002-02-27 | 2005-08-31 | Pfizer Products Inc. | Acc inhibitors |
| AU2003242252A1 (en) | 2002-06-07 | 2003-12-22 | Kyowa Hakko Kogyo Co., Ltd. | Bicyclic pyrimidine derivatives |
| KR20050062645A (ko) | 2002-11-01 | 2005-06-23 | 다케다 야쿠힌 고교 가부시키가이샤 | 신경병증의 예방 또는 치료제 |
| US7960369B2 (en) | 2002-11-08 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Receptor function regulator |
| AU2003284596A1 (en) | 2002-11-22 | 2004-06-18 | Takeda Pharmaceutical Company Limited | Imidazole derivative, process for producing the same, and use |
| CA2527691C (en) | 2003-05-30 | 2013-01-22 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| US7534887B2 (en) | 2003-09-30 | 2009-05-19 | Takeda Pharmaceutical Company Limited | Thiazoline derivative and use of the same |
| WO2005058823A1 (ja) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | ウレア誘導体、その製造法及び用途 |
| CA2551610A1 (en) | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
| US7585880B2 (en) | 2003-12-26 | 2009-09-08 | Takeda Pharmaceutical Company Limited | Phenylpropanoic acid derivatives |
| JP4875978B2 (ja) | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | アミノフェニルプロパン酸誘導体 |
| US7517910B2 (en) | 2004-03-30 | 2009-04-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| WO2005108370A1 (ja) * | 2004-04-16 | 2005-11-17 | Ajinomoto Co., Inc. | ベンゼン化合物 |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| CA2605778A1 (en) | 2005-04-20 | 2006-10-26 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| GB0511851D0 (en) * | 2005-06-11 | 2005-07-20 | Astrazeneca Ab | Chemical compounds |
| WO2007013689A1 (ja) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | シクロプロパンカルボン酸化合物 |
| WO2007013694A1 (ja) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | フェノキシアルカン酸化合物 |
| PE20070338A1 (es) | 2005-08-10 | 2007-04-16 | Takeda Pharmaceutical | Derivados heterociclicos como agentes terapeuticos para diabetes |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| EP1966221A1 (en) * | 2005-12-22 | 2008-09-10 | AstraZeneca AB | Pyrimido- [4, 5-]-oxazines for use as dgat inhibitors |
| EP1996567B1 (en) * | 2006-02-15 | 2013-09-18 | AbbVie Inc. | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| CL2007001873A1 (es) | 2006-06-27 | 2008-01-04 | Takeda Pharmaceutical | Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo |
| WO2008047821A1 (en) | 2006-10-18 | 2008-04-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| JP5260507B2 (ja) | 2006-10-19 | 2013-08-14 | 武田薬品工業株式会社 | インドール化合物 |
| JP2008179621A (ja) * | 2006-12-28 | 2008-08-07 | Taisho Pharmaceutical Co Ltd | 含窒素飽和複素環化合物 |
| EP2128163A1 (en) * | 2007-01-25 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Spiro-ring compound |
| EP2128138A1 (en) | 2007-01-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Pyrazole compound |
| EP2118066A1 (en) | 2007-02-09 | 2009-11-18 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of ppar-gamma |
| WO2008136428A1 (ja) | 2007-04-27 | 2008-11-13 | Takeda Pharmaceutical Company Limited | 含窒素５員複素環化合物 |
| EP2157859A4 (en) | 2007-06-19 | 2011-01-12 | Takeda Pharmaceutical | INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE |
| NZ587096A (en) | 2008-03-26 | 2011-11-25 | Global Alliance For Tb Drug Dev | Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones |
| US8815876B2 (en) | 2008-07-16 | 2014-08-26 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and methods of use thereof |
| EP2351743A4 (en) | 2008-10-27 | 2012-05-09 | Takeda Pharmaceutical | BICYCLIC COMPOUND |
| JP2010102718A (ja) | 2009-11-27 | 2010-05-06 | Toshiba Corp | 情報処理装置 |
| EA201390794A1 (ru) | 2010-11-30 | 2013-11-29 | Такеда Фармасьютикал Компани Лимитед | Бициклическое соединение |
| WO2012108478A1 (ja) | 2011-02-09 | 2012-08-16 | 武田薬品工業株式会社 | 単環化合物 |
-
2011
- 2011-04-26 MA MA35387A patent/MA34245B1/fr unknown
- 2011-04-26 KR KR1020127030925A patent/KR20130094211A/ko not_active Withdrawn
- 2011-04-26 AR ARP110101434A patent/AR080969A1/es unknown
- 2011-04-26 EA EA201291115A patent/EA021698B1/ru not_active IP Right Cessation
- 2011-04-26 EP EP11722184.6A patent/EP2563765B1/en active Active
- 2011-04-26 NZ NZ603777A patent/NZ603777A/xx not_active IP Right Cessation
- 2011-04-26 ES ES11722184.6T patent/ES2546130T3/es active Active
- 2011-04-26 GE GEAP201112904A patent/GEP20146178B/en unknown
- 2011-04-26 US US13/094,015 patent/US8703758B2/en not_active Expired - Fee Related
- 2011-04-26 JP JP2012547392A patent/JP5693611B2/ja not_active Expired - Fee Related
- 2011-04-26 BR BR112012027648A patent/BR112012027648A2/pt not_active IP Right Cessation
- 2011-04-26 CA CA2797767A patent/CA2797767A1/en not_active Abandoned
- 2011-04-26 UY UY0001033354A patent/UY33354A/es not_active Application Discontinuation
- 2011-04-26 PH PH1/2012/502347A patent/PH12012502347A1/en unknown
- 2011-04-26 CN CN201180031899.8A patent/CN103025716B/zh not_active Expired - Fee Related
- 2011-04-26 TW TW100114410A patent/TW201206911A/zh unknown
- 2011-04-26 WO PCT/JP2011/060616 patent/WO2011136385A1/en not_active Ceased
- 2011-04-26 SG SG2012086880A patent/SG185759A1/en unknown
- 2011-04-26 UA UAA201213528A patent/UA108102C2/ru unknown
- 2011-04-26 AU AU2011246004A patent/AU2011246004A1/en not_active Abandoned
-
2012
- 2012-11-26 CR CR20120598A patent/CR20120598A/es not_active Application Discontinuation
- 2012-11-26 ZA ZA2012/08895A patent/ZA201208895B/en unknown
- 2012-11-27 EC ECSP12012311 patent/ECSP12012311A/es unknown
- 2012-11-27 CO CO12214563A patent/CO6640253A2/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| MA34245B1 (fr) | 2013-05-02 |
| CA2797767A1 (en) | 2011-11-03 |
| KR20130094211A (ko) | 2013-08-23 |
| CR20120598A (es) | 2013-02-19 |
| ES2546130T3 (es) | 2015-09-18 |
| CN103025716A (zh) | 2013-04-03 |
| BR112012027648A2 (pt) | 2019-09-24 |
| AR080969A1 (es) | 2012-05-23 |
| US8703758B2 (en) | 2014-04-22 |
| CO6640253A2 (es) | 2013-03-22 |
| CN103025716B (zh) | 2014-12-24 |
| UA108102C2 (uk) | 2015-03-25 |
| AU2011246004A1 (en) | 2012-11-29 |
| SG185759A1 (en) | 2012-12-28 |
| TW201206911A (en) | 2012-02-16 |
| GEP20146178B (en) | 2014-10-10 |
| ECSP12012311A (es) | 2013-05-31 |
| JP2013525262A (ja) | 2013-06-20 |
| EP2563765B1 (en) | 2015-05-27 |
| EA201291115A1 (ru) | 2013-04-30 |
| EA021698B1 (ru) | 2015-08-31 |
| US20110263562A1 (en) | 2011-10-27 |
| UY33354A (es) | 2011-12-01 |
| PH12012502347A1 (en) | 2014-10-14 |
| WO2011136385A1 (en) | 2011-11-03 |
| JP5693611B2 (ja) | 2015-04-01 |
| EP2563765A1 (en) | 2013-03-06 |
| ZA201208895B (en) | 2014-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ603777A (en) | Bicyclic compound derivatives and their use as acc inhibitors. | |
| JP2013525262A5 (enExample) | ||
| AU2014312245B2 (en) | Heterocyclic compounds and methods of use | |
| PE20142099A1 (es) | Derivados de sulfonamida | |
| EA201171004A1 (ru) | Пиридазиноновые соединения | |
| PE20081704A1 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa | |
| MX2012015023A (es) | Derivado novedoso de nicotinamida o sal del mismo. | |
| NZ616298A (en) | Aryl-or heteroaryl-substituted benzene compounds | |
| EA202190116A1 (ru) | Агент для профилактики или лечения спинальной мышечной атрофии | |
| ME02664B (me) | Derivati premeštanja piridina u toku transfekcije inhibitora (ret) kinaze | |
| EA201000947A1 (ru) | Производные тиазола, применимые в качестве ингибиторов киназы pi3 | |
| PE20160115A1 (es) | Compuestos derivados de imidazol como inhibidores de protein quinasa | |
| RU2010106854A (ru) | Производные 2-аза-бицикло[3.3.0]октана | |
| RU2014142598A (ru) | Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в | |
| ES2564010T3 (es) | Composición farmacéutica para tratar o prevenir el glaucoma | |
| RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
| WO2008142986A1 (ja) | Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有する含窒素複素環誘導体 | |
| RU2014107463A (ru) | Селективные ингибиторы протеинкиназ | |
| EA022420B1 (ru) | Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5) | |
| EA201171000A1 (ru) | Производные азаспиранилалкилкарбаматов в форме 5-членных гетероциклов, способ их получения и применение в терапии | |
| PE20120356A1 (es) | Compuestos para el tratamiento de trastornos metabolicos | |
| CA3120351A1 (en) | Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers | |
| EA201071012A1 (ru) | Производные азетидинов, способ их получения и применение их в терапии | |
| CA2978627A1 (en) | Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance | |
| AU2018326721A1 (en) | Compounds and compositions for IRE1 inhibition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2016 BY CPA GLOBAL Effective date: 20150313 |
|
| LAPS | Patent lapsed |